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 39 
•  Functional disorders (i.e., interstitial cystitis/painful bladder syndrome and irritable 40 
bowel syndrome) are associated with hyperexcitability of afferent nerves innervating 41 
the urinary tract and the bowel respectively.   42 
• Various non-5-HT3 receptor mRNA transcripts are expressed in mouse urothelium and 43 
exert functional responses to 5-HT. 44 
•  Whilst 5-HT3 receptors were not detected in mouse urothelium, 5-HT3 receptors 45 
expressed on bladder sensory neurons plays a role in bladder afferent excitability under 46 
both normal conditions and in a mouse model of chronic visceral hypersensitivity 47 
(CVH). 48 
• These data suggest that the role 5-HT3 receptors play in bladder afferent signaling 49 
warrants further study as a potential therapeutic target for functional bladder disorders. 50 
 51 
 52 
Abstract 53 
Serotonin (5-HT) is an excitatory mediator, which in the gastrointestinal (GI) tract, plays 54 
a physiological role in gut-brain signaling and which is dysregulated in functional GI 55 
disorders such as irritable bowel syndrome (IBS). Patients suffering from IBS frequently 56 
suffer from urological symptoms characteristic of interstitial cystitis/painful bladder 57 
syndrome, which manifests due to cross-sensitization of shared innervation pathways 58 
between the bladder and colon. However, a direct modulatory role of 5-HT in bladder 59 
afferent signaling and its role in colon-bladder neuronal crosstalk remain elusive. The 60 
aim of this study was to investigate the action of 5-HT on bladder afferent signaling in 61 
normal mice and mice with chronic visceral hypersensitivity (CVH) following 62 
trinitrobenzenesulfonic acid (TNBS) induced colitis. Bladder afferent activity was 63 
recorded directly using ex vivo afferent nerve recordings. Expression of 14 5-HT receptor 64 
subtypes, the serotonin transporter (SERT) and 5-HT producing enzymes were 65 
determined in the urothelium using RT-PCR. Retrograde labelling of bladder projecting 66 
dorsal root ganglion (DRG) neurons was used to investigate expression of 5-HT3 67 
receptors using single cell RT-PCR, while sensory neuronal and urothelial responses to 68 
5-HT were determined by live cell calcium imaging. 5-HT elicited bladder afferent firing 69 
predominantly via 5-HT3 receptors expressed on afferent terminals. CVH animals 70 
showed a downregulation of SERT mRNA expression in urothelium, suggesting 71 
increased 5-HT bioavailability. Granisetron, a 5-HT3 antagonist, reversed bladder 72 
afferent hypersensitivity in CVH mice. These data suggest 5-HT exerts a direct effect on 73 
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bladder afferents to enhance signaling.5-HT3 antagonists could therefore be a potential 74 
therapeutic target to treat functional bladder and bowel disorders.          75 
  76 
Introduction  77 
Information regarding the state of bladder distension is carried via sensory afferents that 78 
project via the pelvic and hypogastric nerves into the dorsal horn of the spinal cord, 79 
feeding into autonomic reflex and micturition centers within the brainstem to maintain 80 
continence (see Grundy et al. 2018a for review). Bladder afferents are found innervating 81 
both the detrusor smooth muscle and the urothelium (Spencer et al., 2018), consisting 82 
of myelinated Ah fibres and unmyelinated C fibres that exhibit polymodal sensitivity to a 83 
host of mechanical and chemical stimuli (Su and Gebhart, 1998; Zagorodnyuk et al., 84 
2006; Zagorodnyuk et al., 2007). Hypersensitivity of these bladder afferents to bladder 85 
distension may underlie the symptoms of urgency, frequency and nocturia in urological 86 
disorders such as overactive bladder syndrome (OAB)  and interstitial cystitis/painful 87 
bladder syndrome (IC/PBS).   88 
 89 
Serotonin (5-HT) is a key neuromodulator, regulating enteric and viscerosensory function 90 
as well as acting in the central nervous system (Berger et al., 2009; Gershon and Tack, 91 
2007; Grundy, 2008). Out of the seven members of the 5-HT receptor family (5-HT1-7), 92 
six are G-protein coupled receptors (GPCRs) and one,  the 5-HT3 receptor is a ligand-93 
gated ion channel (McCorvy and Roth, 2015). Within the bladder, activation of 5-HT1A, 94 
5-HT 2 and 5-HT3, but not 5-HT4 and 5-HT7 can generate altered bladder contraction in 95 
rodent models (Chetty et al., 2007; Kodama and Takimoto, 2000; Mittra et al., 2007). 5-96 
HT3A and 5-HT3B are expressed in the bladder urothelial layer and detrusor, where it is 97 
considered to play a role in neurogenic contraction (Chetty et al. 2007), whilst 5-HT 98 
receptor subtypes 5-HT1D, 2A, 4 and 5-HT6 are present in urothelial cells. 5-HT1A, 1B, 1D, 2A, 99 
2B, 2C, 3A, 4, and 5-HT7 have also been reported in urothelium-denuded tissues (Matsumoto-100 
Miyai et al., 2016). However, a modulatory role of 5-HT on bladder afferent excitability 101 
has yet to be explored. 102 
 103 
Significant clinical comorbidity exists between a number of lower urinary tract and colonic 104 
disorders, such that the symptoms of bladder dysfunction, including urinary frequency, 105 
urgency, and pelvic pain are significantly more common amongst IBS patients than in 106 
control groups (Daly and Chapple, 2013; Grundy and Brierley, 2018).  Additionally, one-107 
third of IC patients exhibit concurrent IBS symptoms including abdominal pain, 108 
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discomfort, constipation and/or diarrhea (Aaron and Buchwald, 2001). The origin of these 109 
clinical co-morbidities is embedded within the physiological coordination of pelvic organs 110 
to provide efficient and synchronized defecation and micturition responses, and their 111 
shared innervation pathways within the DRG and spinal cord (Grundy et al., 2019). As 112 
such, sensitization of the afferents innervating one pelvic organ, has the potential to 113 
sensitize adjacent organs via cross-organ sensitization (Brumovsky and Gebhart, 2010; 114 
Christianson et al., 2007; Grundy et al., 2018b; Malykhina, 2007) .  115 
 116 
2,4,6-trinitrobenzene sulfonic acid (TNBS) induced colitis is a commonly used animal 117 
model of IBS, triggering chronic visceral hypersensitivity (CVH) that persists after the 118 
initial inflammation has resolved (Castro et al., 2017; de Araujo et al., 2014; Hughes et 119 
al., 2009; Osteen et al., 2016). Furthermore, it has been shown that these CVH mice 120 
exhibit bladder afferent hypersensitivity and abnormal voiding patterns, characteristic of 121 
an ‘overactive’ phenotype (Grundy et al., 2018b). 5HT plays an essential role in health 122 
and the development of colonic afferent hypersensitivity associated with irritable bowel 123 
syndrome (IBS) in humans (Gershon and Tack, 2007; Grundy, 2008) and animal models 124 
(Keating et al., 2008; Linden et al., 2003; Linden et al., 2005). As such, this raises the possibility 125 
that bladder hypersensitivity associated with TNBS-induced colitis may involve a 5-HT3 126 
receptor dependent mechanism.  127 
 128 
Therefore, we performed bladder afferent recordings to investigate the modulatory action 129 
of 5-HT on primary afferent signaling in mouse urinary bladder and in a TNBS-induced 130 
colitis model of colon-bladder neuronal ‘cross talk’. We also used calcium imaging and 131 
single cell RT-PCR of retrogradely traced bladder-innervating afferent dosral root 132 
ganglion (DRG) neurons to characterise the sensitivity of bladder neurons to 5-HT.     133 
 134 
 135 
  136 
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Methods 137 
All experiments were conducted in Sheffield, UK except the induction of TNBS, the 138 
retrograde tracing studies and dorsal root ganglion (DRG)  experiments (calcium imaging 139 
and single cell RT-PCR) which were performed in Adelaide, Australia. 140 
 141 
Animals 142 
All experiments performed in the UK used C57/ BL6 adult male mice ( 12- 16 weeks old, 143 
25-30 g) from Charles River (Margate, UK). The animals were acclimatized for 7 days in 144 
the laboratory animal husbandry unit under 12-hr light/ 12-hr dark cycle and had free 145 
access to water and food. The animals were anaesthetized with isoflurane and humanely 146 
sacrificed by cervical dislocation according to UK home office legislation ( Scientific 147 
procedure Act 1986) and in compliance with Journal of Physiology’s ethical guidelines 148 
(Grundy, 2015).  149 
 150 
Experiments performed in Australia were approved by and performed in accordance with 151 
the Animal Ethics Committees of the South Australian Health and Medical Research 152 
Institute (SAHMRI; Application # SAM190, SAM195, and SAM281) .  12-16 week male 153 
and female mice were acquired from an in-house C57BL/6J breeding program (JAX 154 
strain #000664; originally purchased from The Jackson Laboratory; breeding barn MP14; 155 
Bar Harbor, ME) within SAHMRI’s specific and opportunistic pathogen-free animal care 156 
facility.  Mice were group housed ( 5 mice per cage)  in specific housing rooms within a 157 
temperature- controlled environment of 22°C and a 12 - hr light/  12- hr dark cycle.  Mice 158 
had free access to food and water.  159 
 160 
 161 
2,4,6-trinitrobenzenesulfonic acid (TNBS) treatment  162 
13-week old anesthetized male mice were intracolonically administered with 2,4,6-163 
trinitrobenzenesulfonic acid (TNBS) 0.01 mL (130 µg mL-1 in 30% ethanol) via a 164 
polyethylene catheter to induce colonic inflammation. Histological examination of colon 165 
and bladder was performed to monitor mucosal architecture and signs of inflammation, 166 
i.e., cellular infiltration, crypts abscesses, and goblet cell depletion (data not shown). In 167 
this study we investigated the effect of TNBS colitis at 2 time points; acute TNBS (3 days 168 
post-treatment) when there is an active inflammatory state (termed acute visceral 169 
hyposensitivity, ‘AVH’) and 28 days post-treatment, when the inflammation has resolved 170 
but the bladder afferent hypersensitivity still persist (termed chronic visceral 171 
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hypersensitivity, ‘CVH’). For ex vivo experiments mice were humanly sacrificed by 172 
cervical dislocation.  173 
 174 
Extracellular afferent nerve recordings 175 
Bladder afferent nerve activity was determined using an ex vivo model previously 176 
described (Daly et al., 2007; Grundy et al., 2018a). The whole bladder and surrounding 177 
tissues (together with its emanating nerve fibers) was placed in a recording chamber (30 178 
mL). The preparation was continuously perfused at a rate of 5 mL minute- 1 with 179 
oxygenated (95%O2/5%CO2) Krebs bicarbonate solution (composition, mM: NaCl 118.4, 180 
NaHCO3 24.9, CaCl2 1.9, MgSO4 1.2, KCl 4.7, KH2PO4 1.2, glucose 11.7) at constant 181 
temperature of 35 °C .  A polythene catheter (0. 28 mm)  was inserted into the urethra to 182 
perfuse the bladder with isotonic saline (0.9% NaCl) or pharmacological reagents using 183 
a perfusion pump ( Genie, Kent, multi- phaser TM model NE- 1000)  with a rate 100 µL 184 
minute- 1.  The bladder dome was punctured at the apex with a syringe needle ( BD 185 
microlanceTM, 19G 2” )  and a dual- lumen catheter was inserted and secured with 186 
suture. One arm of the catheter was connected to a pressure transducer (DTXTM plus 187 
DT-XX, Becton Dickinson, Singapore) to monitor intravesical pressure and the other arm 188 
was connected to the 3 way tap to allow bladder filling (tap closed) or emptying (tap 189 
open). Multiunit pelvic and hypogastric nerves were dissected into a fine branches and 190 
placed into a suction electrode which was attached to a Neurolog headstage ( NL 100, 191 
Digitimer, Ltd, UK) , amplified with an AC amplifier ( NL104)  and filtered ( NL125, band 192 
pass filter. The multi-unit afferent nerve discharge frequency (spikes/sec) was quantified 193 
using a spike processor ( Digitimer D130). The signal was visualized on a computer 194 
running Spike 2 software (Version 7.1, Cambridge Electronic Design, UK).  195 
 196 
Drug application  197 
After a 30-minute stabilization period the bladder was distended by an intravesical 198 
infusion with saline at a rate of 100 µL minute-1 to a maximal pressure 50 mmHg (control 199 
distensions). This was repeated at 10-minute intervals for 30-60 minutes to establish 200 
reproducible afferent responses before starting the protocol. After the control 201 
distensions, pharmacological agents were either perfused into the bladder lumen 202 
(intravesical application) or into the recording chamber (bath application). Following 203 
application of any compound a ‘wash out’ was conducted using either saline 204 
(intravesical) or Krebs (bath application) as appropriate for 30 minutes.  205 
 206 
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Isovolumetric protocol 207 
In order to evaluate the effect of a pharmacological reagents on spontaneous afferent 208 
firing and bladder tone, isovolumetric experiments were conducted. After a 30-60 minute 209 
stabilization period the bladder was filled to an intravesical pressure of 15 mmHg and left 210 
to stabilize for 30 minutes to allow the bladder to accommodate to the intravesical volume 211 
before bath application of agonists or antagonists. Nerve firing and bladder tone were 212 
continuously captured. Bladder contraction was determined as an increase in 213 
intravesical pressure.  214 
 215 
Isolation of urothelial cells  216 
Urothelial cells were isolated as previously described (Daly et al., 2014). The bladder 217 
was dissected longitudinally under a stereo microscope to expose the urothelium to the 218 
media (fresh Modified Eagle Media (MEM) (Gibco®) containing 0.7% HEPES and 1% 219 
antibiotic-antimycotic (PSF) solution (Gibco®) at 37°C and transferred to a Sylgard® 220 
(Dow Corning) coated dish. The tissue was stretched and pinned. The media was 221 
removed and replaced with 2.5 mg/mL dispase in MEM at 37°C . The bladder was 222 
incubated in dispase for 2 hours at room temperature. After the dispase had been 223 
aspirated, the urothelium was gently scraped with a scalpel under the stereo microscope 224 
and the cells were immediately placed in 0.5% trypsin-EDTA (Gibco®). The solution was 225 
incubated at 37 °C for 10 minutes, and gently triturated every a few minutes . The trypsin-226 
EDTA was deactivated by adding pre-warm MEM with 10 % Fetal Bovine Serum (FBS) 227 
(Gibco®). The cell suspension was centrifuged at 1500 rpm, 4 °C for 15 minutes . The 228 
solution was gently aspirated and the pellet was resuspended in pre-warmed 229 
Keratinocyte-serum free medium (K-SFM) and centrifuged at 1500 rpm, 4 °C for 15 230 
minutes. For calcium imaging experiment, the cells were resuspended in K-SFM 200 µL 231 
and plated on collagen IV (Sigma Aldrich Poole, UK) coated coverslips in a 12 wells plate 232 
and incubated in 5% CO2-95% O2 at 37 °C overnight . For PCR experiments, the cell 233 
pellet was washed by adding PBS and centrifuged at 1000 rpm, 4 °C for 5  minutes and 234 
stored at -80 °C for RNA isolation process . 235 
 236 
Reverse-transcription PCR (RT-PCR) 237 
Urothelial cell pellets were used in this experiment. The total RNA was extracted using 238 
an RNeasy mini Kit (Qiagen, Valencia, CA, USA. RNA was transcribed to cDNA by High 239 
Capacity cDNA Reverse Transcription Kit with RNase Inhibitor ( Applied Biosystems, 240 
Carlsbad, CA, USA) . PCR reactions were prepared using Gotaq® Green Master Mix 241 
(Promega M7121) according to manufacturer’s instructions (Total volume 25 µL; Gotaq 242 
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Gotaq® Green Master Mix 12.5 µL, forward and reward primers 2.5 µL, cDNA for 50 ng 243 
RNA, nuclease-free water was adjusted to volume 25 µL). The samples were run in 244 
triplicate. The list of exon spanning primers used is summarised in Table 1. ß- actin was 245 
used as a house keeping gene and either brain, DRG neurons, or duodenum was used 246 
as positive control.  For negative control reactions, distilled water was used instead of 247 
cDNA samples. All the PCR products of detected 5-HT receptors were checked by DNA 248 
sequencing and all genes showed a high percentage matching (96-100%) to the original 249 
sequences, suggesting that the designed primers were efficient and the detected 5-HT 250 
receptor results were valid (data not shown). 251 
 252 
Table 1 Summary of primer sequences used in RT-PCR  253 
Receptor 
subtypes 
Accession 
number 
Primer sequences 
Produc
t size 
(bps) 
Positive 
control 
5-HT1A  NM_008308 FW:   5’ TAAGAACTTCCCGCTCCAGT 3’ 103 Brain 
  RW: 5’ AGAAATGCAAGGGGATCTCC 3’   
5-HT1B  NM_010482 FW: 5’ CCAACACACAATAAATGCTCCT3’ 135  DRG 
    RW: 5’ CCAAGTCAAAGTGCGAGTCT 3’     
5-HT1D  NM_008309 FW: 5’TACAAACACCCCTACTAAACGC 3’ 310 DRG  
    RW: 5’ATGAGTGTTCAGCGTTGGTT 3’     
5-HT1F NM_008310 
FW: 5’GACCAGAGCCCCTTAGCTTC 3’ 340 DRG  
    RW: 5’TGCAGCTTCCGAGTCACAAT 3’     
5-HT2A  NM_172812 FW: 5’ CATCTCCCTGGACCGCTAC 3’ 150 DRG 
    RW: 5’ TCATCCTGTAGCCCGAAGAC 3’     
5-HT2B  XM_006529146 FW: 5’ CCGATTGCCCTCTTGACAAT 3’ 120 DRG 
    RW: 5’ GGCACAGAGATGCATGATGG 3’     
5-HT2C  NM_008312 FW: 5’ TGAAACTGGTTGCTTAAAACTGA 3’ 126 DRG  
    RW: 5’ AGCTGCTACTGGACTTATGGA 3’     
5-HT3A  NM_013561 FW: 5’ CCACCTTCCAAGCCAACAAG 3’ 128 DRG 
    RW: 5’ CTCCCTTGGTGGTGGAAGAG 3’     
5-HT3B  NM_020274 FW: 5’ TGATTCTTCTGTGGTCCTGC 3’ 154 DRG 
    RW: 5’ GCCTCAGCCCAGTTGTAAAC 3’     
5-HT4  NM_008313 FW: 5’ ATGTTCTGCCTGGTCCGG 3’ 162  DRG 
    RW: 5’ GCCTCCCAACATTAATGCGA 3’     
5-HT5A  NM_008314 FW: 5’ AAGACCAACAGCGTCTCCC 3’ 124 Brain 
    RW: 5’ TCCACGTATCCCCTTCTGTC 3’     
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5-HT5B NM_010483 FW: 5’  TCTCCTTCGACGTGTTGTGC 3’ 469  Brain 
    RW: 5’  GAGTCTCCGCTTGTCTGGAA 3’     
5-HT6 NM_021358 FW: 5’  TGGGCAAAGCTCGAACATCT 3’ 386 Brain 
    RW: 5’  GTCACATACGGCCTGAGCTAT 3’     
5-HT7 NM_008315 FW: 5’  AAGTTCTCAGGCTTCCCACG 3’    485 DRG  
    RW: 5’  CAGTTTTGTAGCACAAACTCGCT 3’     
TPH1  NM_009414 FW: 5’  CTAGGAGTTCATGGCAGGTG3’ 83 Duodenum 
    RW: 5’ TTTCGAGTCTTTCACTGCACT 3’     
TPH2  NM_173391 FW: 5’ TTCCCAGGGTCGAGTACACA 3’ 216 Brain 
    RW: 5’ GTCTCTTGGGCTCAGGTAGC 3’     
SERT NM_010484 FW: 5’ CATAGCCAATGACAGACAG 3’ 352 Duodenum 
    RW: 5’CAAAACCAAGAACCAAGAC 3’     
 254 
 255 
Retrograde tracing of bladder innervating DRG neurons 256 
A small aseptic abdominal incision was made in anesthetised (isoflurane 2-4 % in 257 
oxygen) mice. Cholera toxin subunit B conjugated to AlexaFluor® 488 (CTB-488; 0.5 % 258 
diluted in 0.1 M phosphate buffered saline (PBS); ThermoFisher Scientific) was injected 259 
at four sites into the bladder wall (2µL / injection) using a 5 µl Hamilton syringe attached 260 
to a 23-gauge needle. The abdominal incision was sutured closed and analgesic 261 
(Buprenorphine; 2.7µg / 30g) and antibiotic (Ampicillin; 50 mg/kg) given subcutaneously 262 
as mice regained consciousness. Mice were allowed to recover, housed individually and 263 
monitored for four days, in order to visualize CTB-labelled afferent neurons in the DRG. 264 
 265 
Isolation of DRG neurons  266 
DRGs from lumbosacral (L5-S1) spinal levels of the mouse spinal cord, which 267 
correspond to the pelvic innervation of the bladder, were isolated and incubated in Hanks 268 
balanced salt solution (HBSS) (pH 7.4) containing collagenase (4mg/mL), and dispase 269 
(4.5mg/mL), at 37°C for 30 minutes . The collagenase/dispase solution was aspirated 270 
and replaced with HBSS containing collagenase (4mg/mL) for 10 minutes at 37°C . The 271 
collagenase solution was aspirated and replaced with 600µl DMEM (GIBCO) containing 272 
10% FCS (Invitrogen), 2鳥mM L-glutamine (GIBCO), 100 たM MEM non-essential amino 273 
acids (GIBCO) and 100鳥mg/ml penicillin/streptomycin (Invitrogen). Neurons were 274 
dissociated via trituration with a Pasteur pipette and spot plated onto 15 mm coverslips 275 
coated with laminin (20 たg/mL) and poly-D-lysine (800鳥たg/鳥mL) and maintained in an 276 
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incubator at 37鳥°C in 5% CO2. Calcium imaging recordings were performed on DRG 277 
neurons 18-30hrs post isolation.  278 
 279 
Single cell RT-PCR  280 
Cells were used 3-8 hrs after plating a cover slips. Under continuous perfusion of sterile 281 
and RNA-/DNase-free PBS, retrogradely traced single DRG neurons (N=3/group; HC: 282 
total 77 cells, CVH: total 74 cells; 23-27 cells per mouse) were identified using a 283 
fluorescent microscope and picked using a micromanipulator into the end of a fine glass 284 
capillary. The glass capillary containing the cell was then broken into a sterile Eppendorf 285 
tube containing 10 L of lysis buffer with 1µl DNAse (TaqMan Gene Expression Cells-286 
to-CT Kit; Life Technologies). Samples were treated according to manufacturer’s 287 
instructions for cDNA synthesis using SuperScript™ VILO™ cDNA Synthesis Kit 288 
(ThermoFisher Scientific) and RT-PCR using TaqMan™ Universal Master Mix 289 
(ThermoFisher Scientific). Ready-made TaqMan probes were purchased from 290 
LifeTechnologies (Htr3a: Mm00442874_m1). For each coverslip of cells, a bath control 291 
was also taken and analysed together with cells. A total of 45 cycles was run and only 292 
samples with a complete amplification curve were considered as positive. After lysis and 293 
termination of DNAse treatment, samples were immediately frozen on dry ice and stored 294 
at -80C until cDNA synthesis was performed. Tubulin-3 expression (Mm00727586_m1) 295 
served as a neuronal marker and positive control and for every coverslip a bath control 296 
was taken and analysed together with other samples. GFAP expression 297 
(Mm01253033_m1) was measured to exclude contamination with glial cells. PCR 298 
products were stored at -20C and resolved on a 3-4% TBE agarose gel (UltraPure 299 
Agarose 1000, cat#16550-100, Invitrogen). All samples were visualized by adding 1µl of 300 
Midori Green Direct (NIPPON Genetics) to 20µl of sample and 5µl of samples was loaded 301 
onto wells. A 20bp marker (BioRad) was used to check for correct size.  302 
 303 
Quantitative real-time RT-PCR 304 
To determine the quantitative expression of TPH1 2 and SERT in urothelial cell samples 305 
from sham and TNBS treated animals, quantitative RT-PCR was used. The quantification 306 
of mRNA expression determined using TaqMan Gene Expression Master Mix (Applied 307 
Biosystems 4374657). The reaction was prepared on ice and mixed in Hard-Shell® Thin-308 
Wall 96-Well Skirted PCR Plates (BIO-RAD, HSP-9665). Prior to running the reactions, 309 
the plates were covered with MicroAmpTM Optical Adhesive Film for 96-Well Plates 310 
(Applied Biosystems, 43111971) and centrifuged briefly to spin down the contents and 311 
11 
 
eliminate any air bubbles from the solutions. The reaction for each sample and gene was 312 
run in duplicate. DNase free water was used to replace cDNA as a negative control for 313 
each gene and plate. PCR reactions were performed in a BIO-RAD CFX96 TouchTM 314 
Real-time thermocycler (C1000 TouchTM Thermal Cycler, Bio-Rad Laboratories Ltd. 315 
Hercules, USA). Results were expressed as relative expression to the housekeeping 316 
gene GAPDH (1/〉Ct), and fold change was calculated using the equation 2−〉(〉Ct). 317 
 318 
Calcium imaging 319 
Cultured DRG neurons (18-30 hours)  or isolated urothelial cells were loaded with 2 たM 320 
fura- 2-acetoxymethyl ester ( Fura- 2)  for 15 minutes at 37°C and washed with HEPES 321 
buffer (10mM, NaCl 142mM, KCl 2mM, glucose 10mM, CaCl2 2mM, MgCl2 1mM, HEPES 322 
10mM; pH 7.4) for 30 minutes prior to imaging at room temperature (23°C ). Fura-2 was 323 
excited at 340 and 380鳥nm. Fluorescence images were obtained every 5s using a 20x 324 
objective.  Retrogradely traced bladder-innervating DRG neurons were identified by the 325 
presence of the CTB- 488 tracer. Data were recorded and analysed using MetaFluor 326 
software.  After an initial baseline reading to ensure cell fluorescence was stable ( an 327 
indication of healthy cells), DRGs and/or urothelial cells were stimulated with either 5-HT 328 
( 100 µM) , 2- Me- 5HT ( 100 µM) in the absence or presence of granisetron (1 µM), and 329 
changes in intracellular calcium [ Ca2+ ] i, were monitored in real- time.  Ionomycin or KCl 330 
(40 mM) was applied as a positive control for cell viability.   331 
 332 
Drugs and solutions 333 
5-hydroxytryptamine (5-HT) and 5-methoxytryptamine (5-MT) were obtained from Sigma 334 
Aldrich, UK. 2- Methy5- hydroxytrptamine (2- Me- 5- HT)  was obtained from 335 
Tocris/ Bioscience, UK. Granisetron hydrochoride was obtained from LKT Laboratories, 336 
USA. ML- 9 was obtained from Cayman Chemical. Y- 27632 was obtained from 337 
Chemdea, USA.  338 
 339 
Data analysis  340 
Spontaneous afferent firing (also referred to as baseline) was determined by measuring 341 
mean action potential firing rate over 10 seconds either at rest (before a drug application 342 
or before a distension). This is defined as the afferent activity arising from the bladder in 343 
the absence of a stimuli (mechanical or chemical). Mechanosensitive afferent firing was 344 
determined by performing ramp distension of the bladder (as described above) and 345 
measuring the afferent discharge at various intravesical pressure points using a custom-346 
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built script from SPIKE 2 version 7 (CED, UK). Data are expressed as means ± SEM. 347 
Statistical analysis was analyzed using one- or two-way analysis of variance (ANOVA) 348 
with Dunnett’s or Tukey multiple comparison or Student’s t test, where appropriate. The 349 
statistical analysis were considered significant at *P<0.05, **P<0.01, ***P<0.001, 350 
****P<0.0001. 351 
 352 
  353 
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Results 354 
Intravesical administration of 5-HT agonists excites bladder afferent nerves 355 
In order to determine if bladder afferents functionally express 5-HT receptors, we 356 
investigated the effects of various 5-HT receptor agonists on ex-vivo bladder afferent 357 
nerve activity. We found that intravesical infusion of 5- HT (100 µM), evoked a dramatic 358 
and sustained increase in baseline afferent nerve firing compared to intravesical saline 359 
(Fig. 1A, 1B). The receptor mechanisms underlying this effect were determined by 360 
comparing the responses to 2-Me-5-HT, a selective 5-HT3 agonist (100 µM), with 5-MT 361 
(100 µM) a compound which exhibits selectivity for the GPCR family of 5-HT receptors 362 
including 5-HT1, 5-HT2 and 5-HT4-7. The responses to application of 5-HT and 2-Me-5-363 
HT were comparable. However while the response to 5-MT, was significantly increased 364 
relative to baseline, the magnitude of the firing was reduced compared to that of 5-HT 365 
and 2-Me-5-HT (Fig. 1C, 1D). These data suggest that multiple 5-HT receptors may 366 
influence bladder afferent firing, and that this may occur via both direct and indirect 367 
mechanisms.  368 
 369 
5-HT receptors are expressed on bladder urothelium  370 
Given the established role of the urothelium as a sensory structure, we wanted to 371 
determine if the effects of intravesical 5-HT on bladder afferent firing were secondary to 372 
activation of urothelial cells or a consequence of direct activation of primary afferent 373 
endings innervating the bladder. To this end we investigated serotonergic receptor 374 
expression in the bladder urothelial layer using RT-PCR. The expression profile for the 375 
various 5- HT receptors in the urothelium is shown in Figure 2. Overall, 5-HT1A, 5-HT1B, 376 
5-HT1D, 5-HT2A, 5-HT2B, 5-HT4, 5-HT6, and 5-HT7 receptors were all detected. In contrast, 377 
5-HT1F, 5-HT2C, 5-HT3A, 5-HT3B or the 5-HT5A, 5-HT5B receptors were not detected in the 378 
bladder urothelium. Moreover, expression of the 5-HT producing enzymes, tryptophan 379 
hydroxylase-1, and 2 (TPH-1 and TPH-2), and the sodium-dependent serotonin 380 
transporter (SERT) transcripts were also examined using PCR and all three were shown 381 
to be expressed in the urothelium (Fig. 2). This finding raises the possibility of an 382 
endogenous source of 5-HT in the bladder wall.  383 
  384 
Stimulation of non-5HT3 receptors on the urothelium can evoke urothelial cell 385 
activation 386 
Calcium imaging of isolated primary mouse urothelial cells (PMUCs) was conducted to 387 
investigate the functionality of 5-HT receptors in the urothelium. Incubation of PMUCs 388 
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with 5-HT triggered an increase in intracellular Ca2+ indicative of cellular activation. 389 
Consistent with our RT-PCR data identifying an absence of 5-HT3 receptor expression 390 
in the urothelium, both the magnitude of the response to 5-HT and the number of 391 
responding cells was unchanged following incubation with the 5-HT3 selective antagonist 392 
granisetron (Fig. 3B, 3C).  393 
 394 
Activation of 5-HT receptors by bath application of agonist alters afferent nerve 395 
firing from the bladder and induces contraction of the detrusor 396 
To elucidate if the 5-HT effects on bladder afferent activity are secondary to induced 397 
detrusor contraction, we applied agonists, antagonist and muscle contraction inhibitors 398 
under isovolumetric bladder conditions to determine their effect on spontaneous afferent 399 
firing and associated intravesical pressure changes. A representative trace of 400 
extraluminal 5-HT application on bladder afferent firing and intravesical pressure is 401 
illustrated in Fig. 4A. We found that 5-HT (100 µM), 2-Me-5-HT (100 µM) or 5-MT (100 402 
µM) all evoked a marked increase in bladder afferent nerve firing, and a small but robust 403 
increase in intravesical pressure indicating detrusor contraction (Fig. 4B, 4C). 404 
 405 
The peak afferent response to bath application of 5-HT and 2-Me-5-HT was similar. 406 
Moreover, application of the selective 5-HT3 receptor antagonist, granisetron (1 µM), 407 
significantly attenuated afferent responses to 5-HT. To uncouple the direct effect of 5-408 
HT on the afferent nerves from any indirect nerve response produced by bladder 409 
contraction we used a myosin light chain kinase inhibitor (ML-9, 10 µM) and/or the rho-410 
associated kinase inhibitor (Y-27632, 10 µM) to prevent contraction. Under such 411 
conditions the afferent response to 5-MT was abolished in the absence of contraction, 412 
suggesting that the response to 5-MT was secondary to changes in muscle tone. 413 
Conversely, the afferent response to 2-Me-5-HT persisted despite the absence of 414 
contraction, suggesting that the contractile and nerve responses to 5-HT3 receptor 415 
stimulation were independent (Fig. 4B and 4C). 416 
 417 
Chronic visceral hypersensitivity evoked with intra-colonic TNBS caused altered 418 
mechanosensitivity and increased spontaneous afferent firing from the bladder, 419 
an effect that was reversed by blocking the 5-HT3 receptor. 420 
Bladder hypersensitivity has been described in response to colonic inflammation, a 421 
phenomenon referred to as cross-organ sensitization. Since 5-HT is implicated in colonic 422 
hypersensitivity we investigated the extent to which it may contribute to altered bladder 423 
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afferent signalling in a mouse model of TNBS-induced colonic inflammation. We 424 
examined 2 time points representing acute inflammation (3 days post-treatment) and a 425 
chronic state in which inflammation had resolved (28 days post-treatment). Acute TNBS 426 
treatment had no significant effect on spontaneous nerve firing from the bladder and 427 
caused a moderate (~25% from sham control) decrease of mechanosensitive afferent 428 
firing at 50 mmHg (Fig. 5A). Conversely, in the post-inflammatory CVH state there was 429 
a significant increase in spontaneous bladder afferent firing (~160%) and in the afferent 430 
response to bladder distension (~27%) when compared to sham controls (*P<0.05, Fig 431 
5). Treatment with granisetron (1 µM) prior to 5-HT application normalized both the 432 
spontaneous bladder discharge and the mechanosensitivity observed in the CVH model 433 
(Fig. 5A, 5B).  434 
 435 
SERT mRNA expression was downregulated in urothelial cells of CVH mice. 436 
The attenuated responses in the presence of granisetron implies a role for endogenous 437 
5-HT in bladder hypersensitivity. We hypothesized that there might be a change in 5-HT 438 
bioavailability in the urothelium following chronic visceral hypersensitivity (CVH) induced 439 
by intra-colonic TNBS. Quantitative RT-PCR showed that the level of SERT mRNA 440 
expression was significantly lower in urothelial cells from bladders in TNBS treated mice 441 
compared to sham operated controls (*P<0.05, Fig. 6A). TPH1 and TPH2 mRNA 442 
expression was also reduced, but because of the large variability, especially in TPH1 443 
levels, this did not reach significance (Fig. 6B, 6C). Nevertheless, these data are 444 
consistent with a role for urothelial 5-HT in bladder hypersensitivity.  445 
 446 
Bladder projecting DRG neurons express 5-HT3 receptors in both control and CVH 447 
mice and display functional response to 5-HT and 2-Me-5-HT activation.  448 
To examine if 5-HT3 receptors in the afferent terminals play a role in 5-HT-senstitized 449 
bladder afferent firing, we performed retrograde labelling and single cell RT-PCR to 450 
examine 5-HT3 receptor gene expression in bladder-projecting DRG neurons. The vast 451 
majority of these neurons (91%, 70/77 neurons) expressed 5-HT3 receptors even in 452 
control animals, which is striking given the absence of any previously documented 453 
endogenous source of 5-HT. Moreover, 95% of bladder-innervating DRG isolated from 454 
mice with CVH expressed 5-HT3 (70/74 neurons), showing a small increase in the 455 
number of neurons expressing 5-HT3 occurs during cross-organ sensitization. (Fig. 7A).  456 
 457 
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In addition, we performed calcium imaging on bladder innervating (traced) and non-458 
traced lumbosacral DRG neurons. A representative trace of calcium imaging of 459 
lumbosacral DRG neurons in response to 5-HT (100 µM) and 2-Me-5-HT (100 µM) is 460 
shown in Figure 7B. 60 out of a total of 69 (87%) bladder projecting DRG neurons (traced 461 
neurons) elicited a calcium signal in response to application of 5-HT, moreover a 462 
significantly greater proportion of the traced DRGs responded to 5HT than the non-traced 463 
DRG neurons. This indicates that expression of 5-HT receptors maybe enriched in 464 
bladder neurons compared to the generalized neuronal population. In addition, a similar 465 
proportion of traced neurons (70%, 36/51) showed an increase in Ca2+ influx after the 466 
application of 2-Me-5-HT (Fig. 7C). The magnitude of the Ca2+ response to 5-HT and 2-467 
Me-5-HT was similar in traced and non-traced DRG neurons (Fig. 7D). These data are 468 
consistent with a major contribution of 5-HT3 receptors to 5-HT’s ability to sensitize 469 
bladder afferents and enhance firing.     470 
 471 
Discussion  472 
Over the past decade, a number of studies, including our own, have investigated the 473 
chemical and mechanical stimuli that drive afferent transmission from the bladder. 474 
Despite this, the mechanisms involved in generating bladder hypersensitivity still remain 475 
elusive. There is significant clinical comorbidity between hypersensitivity disorders of the 476 
bladder and hypersensitivity disorders of the colon (such as IBS), pointing to a common 477 
underlying etiology involving dichotomizing afferent fibres between the bladder and 478 
bowel (Grundy and Brierley, 2018; Malykhina, 2007).  Serotonin (5-HT) plays integral 479 
roles in secretion, motility and visceral sensitivity of the GI tract (Grundy, 2008). 480 
However, relatively little is known about how 5HT affects afferent signaling from the 481 
bladder in healthy or hypersensitivity states. In this study we investigated the modulatory 482 
action of 5-HT on primary afferent signaling in the mouse urinary bladder and in a TNBS-483 
induced model of colitis which induces colon-bladder cross-organ sensitization (Grundy 484 
et al., 2018b). 485 
 486 
5-HT increases bladder afferent firing and induces contraction of the detrusor  487 
Stimulation of 5-HT receptors with serotonin caused a large increase in bladder afferent 488 
nerve firing, which was concomitant with a small but significant contraction of the bladder. 489 
When the contraction was blocked using a combination of muscle blockers the sensory 490 
response was significantly attenuated. This suggests that a proportion of the afferent 491 
response to 5-HT occurred via the activation of mechanosensory afferent nerves which 492 
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were activated in response to bladder contraction. However, since the afferent response 493 
to 5-HT was only partially reduced, it is also likely that there was also an additional direct 494 
mechanism by which 5-HT stimulated a receptor(s) on the nerve terminal,  inducing 495 
nerve firing in a mechanism that was independent from changes in the muscle tone.  496 
 497 
Similar to 5-HT, bath application of the selective 5-HT1, 5-HT2, 5-HT4, 5-HT6, and 5-HT7 498 
agonist, 5 methoxy tryptamine (5-MT) also caused an increase in afferent nerve firing 499 
and evoked a small contraction of the bladder. However, when the contraction was 500 
blocked by preincubation with the muscle blockers (Y-27632 and ML-9), the contraction 501 
was lost and the afferent response to 5MT was abolished suggesting that the afferent 502 
response to stimulation of the non-5HT3 receptor populations was secondary to changes 503 
in bladder contraction rather than via a direct action at the afferent terminal. A number of 504 
previous studies have demonstrated that 5-HT can induce contraction of bladder muscle 505 
strips in vitro, however the receptor that mediates the contraction remains controversial. 506 
Hattori et al., (2017) show that both 5-HT and a selective 5-HT2 receptor agonist cause 507 
contraction of the bladder, but a lack of efficacy following pre-incubation of selective 5-508 
HT2 receptor antagonists suggested that the effect was not mediated by the 5-HT2 509 
receptor (Hattori et al., 2017). In another study it was shown that 5-HT potentiates 510 
neurogenic contractions of rat isolated detrusor muscle through both 5-HT7 and 5-HT2c 511 
receptors (Rekik et al., 2011). Moreover, in the guinea pig the contractile response to 5-512 
HT was suggested to be via the 5-HT2, 5-HT3 and 5-HT4 receptors (Yoshida et al., 2002). 513 
 514 
5-HT has a direct effect on afferent firing via the 5-HT3 receptor 515 
Bath application of 2-Me-5-HT caused a robust increase in nerve firing that was not 516 
affected by blocking contractility. 2-Me-5-HT is a potent agonist of both the 5-HT3 and 517 
the 5-HT6 receptor (Glennon et al., 2000) suggesting that activation of either 5-HT3 or 5-518 
HT6  located on the urothelium (in the case of 5HT6) or at the nerve terminal results in 519 
afferent nerve firing from the bladder. Since we did not use a selective 5HT6 receptor 520 
antagonist we cannot determine from these data what contribution 5HT6 made to the 2-521 
Me-5-HT response. Since the role of 5HT6 in the lower urinary tract is relativity 522 
understudied this would warrant further investigation. However in this study we focused 523 
on the 5-HT3 receptor since pre-incubation of the 5-HT3 selective antagonist granisteron 524 
inhibited the 5-HT-mediated increase in bladder afferent nerve firing by ~65%.  Since 5-525 
HT3 receptors were not identified in the urothelium via RT-PCR, this suggests that 526 
stimulation of 5-HT3 receptors can elicit a direct increase in afferent nerve firing by 527 
stimulating receptors on the nerve terminal rather than via an indirect mechanism as a 528 
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result of muscle contraction or urothelial signaling. Our retrograde tracing studies 529 
revealed that the majority of lumbosacral DRG neurons innervating the mouse urinary 530 
bladder (90%) express the 5-HT3 receptor. Furthermore, our functional calcium imaging 531 
showed that the majority of these DRGs exhibit functional responses to 5-HT (87%) and 532 
the 5-HT3 selective agonist, 2-Me-5-HT (70%). In this study we did not stain the afferent 533 
terminals and show expression of 5HT3 in bladder afferent endings, although it is well 534 
established that expression in the cell body where the receptor is synthesized is likely to 535 
be indicative of expression at the afferent terminal. Therefore these data suggest that 5-536 
HT exerts a direct action on 5-HT3 receptor at the terminal endings of the primary 537 
afferents innervating the bladder. This idea is supported by previous studies which show 538 
that 5-HT3 receptors are also located in rat DRG neurons (Nicholson et al., 2003) and 539 
that systemic injection of a 5-HT precursor (5-hydroxytryptophan, 5-HTP), triggers 540 
bladder hyper-excitability in a mechanism mediated by spinal 5-HT3 receptors (Hall et 541 
al., 2015).  542 
 543 
 A recent study has also shown that bladder-projecting neurons in the caudal raphe 544 
nucleus, the area of the brainstem which exhibits supraspinal control of the bladder, also 545 
express serotonin (Ahn et al., 2018), suggesting that serotonergic control of the bladder 546 
could have both peripheral and central components which involve the 5-HT3 receptor. 547 
 548 
5-HT can alter signaling in the urothelium in a mechanism that is independent of 549 
the 5-HT3 receptor 550 
Over the past decade it has become increasingly clear that the urothelium of the bladder 551 
plays an active role in sensation. It is responsive to bladder filling and releases an array 552 
of mediators and neurotransmitters which target underlying afferent nerves to modulate 553 
firing (urothelial- afferent signaling). Since 5-HT receptor agonists altered sensory 554 
signaling from the bladder we wanted to determine what role the urothelium played in 555 
the afferent response. mRNA for  5-HT1A, 5-HT1B, 5-HT1D, 5-HT2A, 5-HT2B, 5-HT4, 5-HT6, 556 
and 5-HT7 receptors were identified in the urothelium and our functional calcium imaging 557 
experiments demonstrated that ~60% of isolated primary urothelial cells were activated 558 
by stimulation with 5-HT. This indicates that there may be functional 5-HT receptors in 559 
the urothelium that could play a role in both autocrine urothelial mechanisms and 560 
paracrine sensory mechanisms. It is important to note that we did not conduct any 561 
western blot analysis or immunocytochemistry to confirm the protein expression of these 562 
receptors in the urothelium, nor did we use an array of selective agonist and antagonists 563 
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in the calcium imaging experiments, this makes it difficult for us to identify which 564 
receptor(s) mediate the calcium responses. However, pretreatment with the 5-HT3 565 
selective antagonist, granisetron had no effect on the magnitude of the calcium signals 566 
or on the numbers of responsive cells. This taken together with the fact that mRNA for 567 
the 5-HT3 receptor was not identified in the urothelium suggests that while the 5-HT3 568 
receptor may be involved in the direct afferent response to 5HT (i.e. at the 5-HT3 receptor 569 
on the primary afferent terminal) it is not involved in urothelial signaling. Further studies 570 
are required to delineate the differntial role that non-5HT3 receptors play in mediating 571 
contractility and urothelial signaling in the bladder.  572 
 573 
5-HT3 receptor mechanisms contribute to bladder hypersensitivity in CVH.  574 
Christianson et al., (2007) demonstrated that 21% of all retrograde traced mouse DRGs 575 
from the colon also  innervated the bladder (dichotomizing neurons) (Christianson et al., 576 
2007).  Since co-morbidities between the bladder and bowel are common, the hypothesis 577 
of ‘cross-organ sensitization’ has emerged. Evidence for this phenomenon has come 578 
from pre-clinical studies identifying that inflammation or injury to one organ, such as the 579 
bowel, can lead to changes in the sensitivity of another closely located organ, such as 580 
the bladder, via these convergent neural pathways. A number of models of colon-bladder 581 
cross organ sensitization have been developed to study this phenomenon, one such 582 
model is the well-established TNBS model of colitis (Antoniou et al., 2016; Grundy et al., 583 
2018b; Malykhina et al., 2006; Qin et al., 2005) . Previous studies using the TNBS 584 
induced colitis model suggest that inflammation of the bowel induces hypersensitivity of 585 
colonic afferents and changes in spinal neural circuitry that persists after the 586 
inflammation as resolved (Brierley and Linden, 2014). This effect is concomitant with 587 
hypersensitivity of the bladder and bladder voiding dysfunction indicative of overactive 588 
bladder syndrome or painful bladder syndrome, without any obvious morphological 589 
changes in bladder structure. Two phases of response have been identified; an acute 590 
phase of visceral hyposensitivity (AVH, <15 days post treatment) and a chronic phase of 591 
visceral hypersensitivity (CVH, >28 days post treatment) (Grundy et al., 2018b). 592 
 593 
The 5HT3 receptor has been linked to intestinal dysfunction in a number of studies. For 594 
example, the selective 5-HT3 antagonists tropisetron and ondansetron significantly 595 
reduce signs of inflammatory damage in the bowel in a TNBS-induced colitis model in 596 
the rat (Motavallian-Naeini et al., 2012; Motavallian et al., 2013). Bioavailability of 5-HT 597 
in the bowel, as measured by expression of the serotonin reuptake transporter (SERT), 598 
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is reduced in mice (Linden et al., 2005), guinea pigs (Linden et al., 2003) and humans 599 
with either inflammatory conditions of the bowel or irritable bowel syndrome (Coates et 600 
al., 2004). In addition, in a Trichinella spiralis  induced model of post-infectious IBS, long-601 
term hypersensitivity of the small intestine was shown to be mediated by changes in 5-602 
HT3 receptor expression (Keating et al., 2008). 603 
 604 
In the present study, after the induction of colitis with TNBS, the afferent response to 605 
bladder distension was actually inhibited by ~20%, suggesting hyposensitivity of the 606 
bladder afferent nerves in the acute phase colitis. However, in the post-inflammatory 607 
pahse of CVH, the afferent response to bladder distension was significantly increased. 608 
This is consistent with previous data (Grundy et al., 2018b), and suggests that there was 609 
long-term hypersensitivity of bladder afferents following inflammation of the bowel. 610 
Interestingly, the distension-induced hypersensitivity was attenuated via pretreatment 611 
with the 5-HT3 selective antagonist granisetron, implicating the 5-HT3 receptor in the 612 
response. The numbers of bladder-projecting DRG neurons expressing 5-HT3 was also 613 
slightly elevated in the CVH phase. 614 
 615 
Interestingly, mRNA for the 5-HT producing enzymes, TPH1 and TPH2, and the 616 
serotonin transporter, SERT was detected in the normal urothelium and in the urothelium 617 
of mice following TNBS. However, in the urothelium of CVH mice we observed a 618 
significant decrease in SERT expression, which may suggest that following colonic 619 
inflammation there were alterations in the bioavailability of 5-HT. This could potentially 620 
lead to reciprocal changes in 5-HT3 receptor sensitivity and bladder afferent 621 
hypersensitivity.  622 
 623 
What is the endogenous source of 5-HT in the bladder?  624 
The majority of 5-HT is the body is produced by enterochromaffin cells in the GI tract 625 
(Gershon and Tack, 2007) and in the CNS. Activation of enterochromaffin cells can lead 626 
to the release of 5-HT and activation of 5-HT3 receptors on colonic afferents innervating 627 
the colonic mucosa (Bellono et al., 2017). In addition, mast cells also synthesize 5-HT 628 
from 5-hydroxytryptophan and express TPH1 in the rat and human gastrointestinal tracts 629 
(Dwyer et al., 2016; Weitzman et al., 1985). However, the endogenous source of 5-HT 630 
in the bladder has yet to be identified. Since the components needed to produce 5-HT 631 
are present in the urothelium (ie TPH1 and TPH2  mRNA), it is possible that urothelial 632 
cells produce and release 5-HT which can then exert actions on afferent nerve fibers 633 
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located in close proximity, or the underlying smooth muscle. Despite the presence of the 634 
molecular architecture responsible for 5-HT synthesis we identified within the urothelium, 635 
there have been no previous reports of 5HT release from the bladder in the literature to 636 
support this idea. (Fitzgerald et al. (2013) showed that there was a significant increase 637 
in the number of mast cells in the bladder at 12 days after colonic TNBS administration 638 
in rats, raising the possibility that in the post-inflammatory state, 5-HT levels in the 639 
bladder rise due to infiltration of circulating mast cells (Fitzgerald et al., 2013). This 640 
mechanism could drive altered sensory activity via an interaction with the 5-HT3 receptor 641 
on the primary afferents. Unfortunately, since we did not measure 5-HT levels or mast 642 
cell numbers in the bladders from our CVH mice this remains speculative. 643 
 644 
Recent studies have demonstrated the presence of 5-HT positive paraneurons in the 645 
mouse urethra which have a close association with urethral afferent nerves (Kullmann et 646 
al., 2018). In our extracellular recordings the primary afferents we recorded from lie in 647 
close proximity to the bladder neck. Early work by Gabella and Davis demonstrated that 648 
the majority of afferent innervation to the bladder lies in the lower 1/3 of the bladder body 649 
(Gabella and Davis, 1998). Since our electrophysiological recordings consist of multi-unit 650 
nerve bundles it is possible that some of the afferents that we recorded from emanated 651 
from the bladder neck and urethra. Moreover, it is also possible that the urethral 652 
paraneurons could provide an endogenous source of 5-HT, which when released in the 653 
urethra either ‘diffuses’ to reach some of the bladder projecting afferents or via the 654 
urethral urothelium alters urothelial- afferent signaling in the bladder body. A recent in 655 
vivo study lends support to this idea showing that 5-HT released by the urothelial cells 656 
located in the urethra can actually activate a urethra-vesical pathway to enhance 657 
contraction of the bladder (Coelho et al., 2018). This is a fascinating area for further 658 
research and further highlights the complexity of signaling in the lower urinary tract.  659 
 660 
Translational Perspectives 661 
These data suggest that 5-HT plays a key role in the modulation of bladder sensory firing 662 
and the generation of visceral hypersensitivity. This may have important implications for 663 
understanding normal function of the bladder and the changes in bladder function that 664 
arise when serotonergic signaling is disrupted, such that occurs in IBS or with depression 665 
and anxiety.  666 
 667 
 668 
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Figures  and legends 
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Figure 1. Intravesically applied 5-HT, 2-Me-5HT and 5-MT stimulated bladder 
afferent firing. (A) Representative trace to illustrate the afferent response to 
intravesical application of 5-HT (100 µM). (B-D) The peak afferent response to 
intravesical application of (B) 5-HT (100 µM), (C) 2-Me-5HT (100 µM) and (D) 5-
MT (100 µM). Overall, 5-HT, 2-Me-5-HT and 5-MT all evoked increased in 
afferent firing above baseline (*P<0.05), paired Student’s t-test. Each dot 
represents data from a single preparation (N).  
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Figure 2.  mRNA expression of 5-HT receptors, TPH1, TPH2, and SERT on 
the mouse urothelium.  An array of 5-HT receptor transcripts were detected in 
mouse urothelial cell lysates (5-HT1A, 1B, 1D, 2A, 2B, 4, 6, 7).  5-HT1F, 2C, 3A, 3B, 5A, and 
5B receptors were not detectable. mRNA expression of TPH1, TPH2, and SERT 
were detected in mouse urothelial cells.  ß-actin was used as a house keeping 
gene.  Duodenum was used as a positive control of TPH1 and SERT.  Brain was 
used as a positive control for TPH2 (N=3 mice per tissue). 
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Figure 3.  5- HT stimulated mouse urothelial cells through a non- 5- HT3 
receptor mechanism.  (A)  A sample trace showing the calcium response of 
isolated primary mouse urothelial cells to 5-HT (100 たM) and ionomycin (5 たM) . 
Each line represents a single urothelial cell. B)  The relative increase of 
intracellular Ca2+ ( Ratio 340/ 380)  in response to 5- HT with and without 
preincubation with granisetron (1 µM), showing that granisetron did not affect 5-
HT repsonses.  ( C)  The percentage of cells responding to 5- HT after pre-
incubation of granisetron, paired Student’s t- test, (5-HT, N=6 mice, n=137 cells 
vs. Granisetron with 5-HT, N=5 mice, n=115 cells), unpaired Student’s t-test. N 
refers to number of animals and n indicates number of cells. 
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Figure 4.  5-HT3 receptors play a role in mediating the action of 5-HT on 
bladder afferent firing and this effect is independent of detrusor 
contraction.  (A) A representative trace showing the effect of bath applied 5-HT 
on afferent nerve firing and detrusor tone. 5HT, 2-Me-5-HT and 5-MT all evoked 
an increase in nerve firing which was concomitant with a small but significant 
bladder contraction. (B) The afferent response to bath application of 5-HT, 2-Me-
5-HT, 5-MT with and without pre- incubation of the 5-HT3 receptor antagonist 
granisetron and/or smooth muscle blockers (Y-27632 and ML-9)  (C) The effect 
of the same pharmacological agents on detrusor contractility. Data are 
represented as mean +/- SEM, each symbol represents a single N number,  
* P<0. 05, * * P<0. 01, * * * P<0. 001, One- way ANOVA with Dunnett’ s multiple 
comparison (N=5-7). 
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Figure 5. Mice with chronic visceral hypersensitivity (CVH) evoked by TNBS 
had increased spontaneous afferent firing and hypersensitivity in response 
to bladder distension.  This effect was partially reversed by application of 
granisetron.  (A).  Afferent firing from bladders taken from sham mice, mice with 
acute visceral hypersensitivity (AVH) and mice with chronic visceral 
hypersensitivity (CVH), showing that firing rate was higher with chronic visceral 
hypersensitivity and partially rescued by application of the 5HT3 receptor 
B A 
C 
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antagonists granisetron. (B).  The afferent response to bladder filling in bladders 
taken from sham mice, mice with acute visceral hypersensitivity (AVH) and mice 
with chronic visceral hypersensitivity (CVH) showing that firing rate was higher 
with chronic visceral hypersensitivity and partially rescued by application of the 
5HT3 receptor antagonists granisetron. * P<0. 05, and One- way ANOVA with 
Dunnett’ s multiple comparison and Two- way ANOVA respectively ( healthy 
control and CVH, N=6; acute TNBS, N=5; CVH, N=6; CVH+granisetron, N=6) . 
(C). The afferent response to bladder filling in bladders taken from normal control 
mice before and after application of granisetron. These data show that in bladders 
taken from healthy control animals granisteron has no effect on the afferent 
response to bladder distension (N=5)  
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Figure 6 SERT mRNA expression in the urothelium was significantly attenuated in 
mice with CVH.  (A)  SERT mRNA expression was significantly reduced in urothelial 
cell cultures from CVH animals compared to control animals (*P<0.05, unpaired 
Student’s t- test healthy control; N=4, CVH; N=6).  (B)  TPH1 and (C)  TPH2 mRNA 
expression was not significantly altered.  (NS , unpaired Student’s t- test healthy control; 
N=4, CVH; N=6). 
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Figure 7. 5-HT and 2-Me-5HT induce calcium transients in bladder-
innervating DRG neurons. (A) A high percentage of bladder projecting DRG 
neurons in both sham (91%) and mice with CVH (95%) express 5-HT3 receptors 
(sham, N=3, n=77; CVH, N=3, n=74; N refers to number of animals, n indicates 
number of DRG neurons). (B) Calcium responses elicited by 5-HT (100 µM) and 
2-Me-5HT (100 µM) from isolated bladder-innervating (traced), and non-traced 
LS DRG neurons. Each line represents an individual neuron. Bladder traced 
neurons are represented in blue, non-traced neurons are represented in black, 
and responding non-traced neurons are represented in orange. (C) Table 
showing number of bladder-innervating and non-traced LS DRG neurons 
responding to 5-HT (100 µM) (N=4 mice) and 2-Me-5HT (100 µM) (N=4 mice). 
The percentage of bladder-innervating neurons responding to either to 5-HT and 
2-Me-5HT is greater than responding neurons from the general DRG population. 
(D) Maximum change in fluorescent ratio (F340/380) of individual neurons in 
response to 5-HT and 2-Me-5HT in bladder-innervating (blue dots) and non-
traced (orange dots) LS DRG. The magnitude of the calcium response elicited by 
5-HT (100 µM) is equivalent to that elicited by 2-Me-5HT (100µM) for both 
bladder-innervating DRGs (p≥0.05, One-way ANOVA, Tukey post-hoc test) and 
in the non-traced DRGs (p≥0.05, One-way ANOVA, Tukey post-hoc test).  
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